新型冠状病毒肺炎防控形势下儿童青少年慢性心力衰竭的临床管理建议

2019年12月我国湖北省武汉市爆发新型冠状病毒(2019-nCoV)感染疫情,目前已蔓延至全国各地,流行病学显示人群对该病毒普遍易感,且患有基础疾病的患者是重症、危重症的高危人群,同时儿童青少年感染病例数正日益增多。慢性心力衰竭儿童因其基础条件差,感染2019-nCoV后将给此类患儿的诊治带来严峻的挑战。结合儿童2019-nCoV感染的临床特点及儿童慢性心力衰竭的诊治要点,在此提出慢性心力衰竭儿童2019-nCoV感染的临床管理建议,以供临床参考。     

Permanent pacemaker implantation after valve and arrhythmia surgery in patients with preoperative atrial fibrillation

1. Download : Download high-res image (313KB)
2. Download : Download full-size image

     

Annular versus supra-annular sizing for transcatheter aortic valve replacement in bicuspid aortic valve disease

BackgroundCT measurement of supra-annular area (SA) has been proposed as an alternative to annular area (AA) for sizing of trancatheter valves in biscuspid aortic valves (BAV). This study examines the reproducibility of SA and AA measurements and their potential impact on downstream transcatheter heart valve sizing and clinical outcomes.Methods44 consecutive patients (mean age: 73 ± 15 years, 57% male) undergoing CTA with subsequent SAPIEN 3 valve insertion for severe bicuspid aortic stenosis (AS) were included. AA was measured at the basal ring. SA was measured by generating a circle defined by the intercommisural distance. AA and SA were measured by 2 independent observers. Baseline characteristics, TAVR procedural data, and discharge echocardiography data were collected.ResultsThe SA was significantly larger than the AA (562 ± 146mm2 vs. 518 ± 112mm2,p = 0.013). Interobserver agreement was high using both techniques (ICC AA = 0.98,p < 0.001; SA = 0.80,p < 0.001), but with narrower limits of agreement with AA measurements (mean difference (limits of agreement): AA = −3mm2 (22; 19), SA = −16mm2 (−92; 76)). AA-based device sizing demonstrated substantial agreement with final valve inserted (κ = 0.72,p < 0.001), while SA demonstrated fair agreement (κ = 0.40,p < 0.001). There was no difference in post TAVR gradients, paravalvular leakage or valve success between patients with concordant sizing between AA and SA, and those in whom SA would have suggested an alternate valve size.ConclusionsSupra-annular sizing is less reproducible than annular sizing, with no difference in procedural complication rates in patients in whom supra-annular sizing would have altered the device size used. These results suggest no role for supra-annular sizing in current clinical practice.     

Infective endocarditis in patients who have undergone transcatheter aortic valve implantation: a review

BackgroundTranscatheter aortic valve implantation (TAVI) has been approved for the treatment of severe aortic stenosis since 2008 and recent trials have shown that TAVI is at least non-inferior to surgical aortic valve replacement (SAVR) with regards to short-term efficacy and safety in patients across all surgical risk profiles. Prosthetic valve endocarditis of the transcatheter heart valve is a feared complication; data on the risk of infective endocarditis (IE) subsequent to TAVI are now gradually emerging.ObjectivesWe set forth to conduct a review of the incidence, diagnosis, microbial aetiologies, prevention, outcome and management of TAVI-IE.SourcesFrom the MEDLINE database we included a total of 12 observational studies and five studies of long-term results from randomized controlled trials.ContentThe incidence of TAVI-IE was reported to be between 0.7% and 3.0% per person-year. The most common microbes were reported to be enterococci, Staphylococcus aureus, streptococci and coagulase-negative staphylococci. International guidelines on prevention strategies of IE recommend good sanitary conditions including cutaneous care, good oral hygiene and good care of dialysis catheters. Antibiotic prophylaxis is recommended by guidelines prior to dental procedures in patients with TAVI; however, evidence is sparse. The majority of the patients included in this review with TAVI-IE had an indication for surgical intervention due to IE (50.0% or more); however, only a small subset of the patients underwent surgery (16.4% or less). The in-hospital mortality was around 25%, i.e. of the same order of magnitude as in prosthetic valve IE in general, but varied substantially between studies (from 11% to 64%).ImplicationsThe US Food and Drug Administration's approval of TAVI in patients at low surgical risk may change the characteristics of patients with TAVI, which may influence the incidence, management, and outcome of patients with TAVI-IE.     

Transcatheter ductus arteriosus stenting in paediatric cardiology: Indications,results and perspectives

1. Download : Download high-res image (88KB)
2. Download : Download full-size image